NCT02805842 (Advagraf) is a Phase 3 clinical trial of Tacrolimus BID in Medication Adherence, sponsored by Rabin Medical Center.

Who is sponsoring NCT02805842?

NCT02805842 is sponsored by Rabin Medical Center.

What drugs are being tested in NCT02805842?

Interventions in NCT02805842: Tacrolimus BID, Advagraf QD.

What condition does NCT02805842 study?

NCT02805842 studies Medication Adherence.

Is NCT02805842 still recruiting?

NCT02805842 is currently status unknown. Last updated 10 July 2016.

Last reviewed 2016-07-10 · How we verify

NCT02805842: Advagraf

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus (ADVAGRAF) in Kidney Transplant Recipients

Status unknown Phase 3 Last updated 10 July 2016

What this trial tests

Phase 3 trial testing Tacrolimus BID in Medication Adherence in 60 participants. Status unknown.

Timeline

1 August 2016

Primary endpoint
1 August 2018

1 August 2018

Quick facts

Lead sponsor	Rabin Medical Center
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 August 2016
Primary completion	1 August 2018
Estimated completion	1 August 2018
Sites	1 location across Israel

Drugs / interventions tested

Tacrolimus BID — full drug profile →
Advagraf QD — full drug profile →

Conditions studied

Medication Adherence — all drugs for Medication Adherence →

Sponsor

Rabin Medical Center

Who can join

Adults 18 to 60, any sex, with Medication Adherence. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Morisky Medical Adherence Assessment questionnaire
Time frame: 2 years
adherence to the Tacrolimus QD administration defined as self-reported number 9on scale from 1-8) of missed drug ingestions scored in Morisky Medical Adherence Assessment questionnaire

Sponsor's own description

Aim The primary objective of this study is to compare medication adherence with medical therapy in patients receiving once-daily versus twice-daily tacrolimus regimens. Participants 60 adult renal transplant patients randomized 1:2 into twice-daily and once-daily tacrolimus groups Outcomes The primary outcome will be medication adherence to the once-daily and twice-daily regimens, measured in terms of implementation. Secondary outcomes will include graft and patient survival, renal function and adverse events. Follow up - 12 months

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.
Mellon L, Doyle F, Hickey A, Ward KD, et al · · 2022 · cited 20× · PMID 36094829 · DOI 10.1002/14651858.cd012854.pub2

Verify or expand the search:

Other recruiting trials for Medication Adherence

Currently open trials in the same condition.

NCT07420634 — Multilevel Ecological and COM-B Determinants of Medication Adherence in Adults With Diabetes · recruiting
NCT06876233 — Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication · NA · recruiting
NCT05624931 — Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa · NA · recruiting
NCT06949774 — INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND) · NA · recruiting
NCT06569290 — Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Sci · NA · active not recruiting

Other Rabin Medical Center trials

Trials by the same sponsor.

NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02805842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
Last refreshed: 10 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02805842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing